Publisher's Synopsis
Cardiovascular disease (CVD) is one of the major diseases which causing premature death in the world. Plasma LDL level is a major determinant of CVD. Statin drugs prove to be big success on reducing 30-40% cholesterol in some people, yet fail far short in others with initial high value of cholesterol. they need 2 or even 3 different drugs to reach the level
Recent genetic studies have shown, one of the key genes, Proprotein convertase subtilisin/kexin type 9(PCSK9), plays a critical role in cholesterol metabolism by controlling the level of low-density lipoprotein receptor (LDLr). In the chapter I, introduction, we explain why study PCSK9 is important to human health. In chapter II . we described a high throughput assay to identify leading inhibitor compound for PCSK9..In the Chapter III, we describe a shotgun proteomic analysis of potential binding partners of PCSK9, some of them such as E38 ubiquitin ligase c-IAP1 could be significant modulators of PCSK9 function. In chapter IV, we discussed the possible role of the PCSK9 in the infectious disease. In Chapter V, we gave the latest progress using PCSK9 inhibitors, including using anti-PCSK9 antibody and anti/PCSK9 SiRNA to treat cardiovascular diseases. In Chapter VI, we discussed the possibility colchicine, PCSK9 and infection disease in TNF-alpha-mediated cytokine storm in COVID-19.
